Your browser doesn't support javascript.
loading
Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.
Wei, Yuhan; Zhang, Jianwei; Fan, Xueke; Zheng, Zhi; Jiang, Xiaoyue; Chen, Dexi; Lu, Yuting; Li, Yingrui; Wang, Miao; Hu, Min; Du, Qi; Yang, Liuting; Li, Hongzhong; Xiao, Yi; Li, Yongfu; Jin, Jiangtao; Wang, Deying; Yuan, Xiangliang; Li, Qin.
Afiliação
  • Wei Y; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Zhang J; Department of Pancreatic and Gastric Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Fan X; Gastroenterology Department, Jincheng People's Hospital, Jincheng, China.
  • Zheng Z; Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Jiang X; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Chen D; Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, China.
  • Lu Y; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Li Y; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Wang M; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Hu M; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Du Q; Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan, China.
  • Yang L; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Li H; Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan, China.
  • Xiao Y; Chongqing Key Laboratory of Molecular Oncology and Epigenetics, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Li Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jin J; Department of Oncology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China.
  • Wang D; Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
  • Yuan X; Department of Intervention Therapy, Zezhou People's Hospital, Jincheng, China.
  • Li Q; Department of Technology Innovation, China National Nuclear Corporation (CNNC) Hexin Information Technology (Beijing) Co., Ltd., Beijing, China.
Front Immunol ; 13: 935552, 2022.
Article em En | MEDLINE | ID: mdl-35874784
The profiling of the tumor immune microenvironment (TIME) is critical for guiding immunotherapy strategies. However, how the composition of the immune landscape affects the tumor progression of gastric cancer (GC) is ill-defined. Here, we used mass cytometry to perform simultaneous in-depth immune profiling of the tumor, adjacent tissues, and blood cells from GC patients and revealed a unique GC tumor-immune signature, where CD8+ T cells were present at a lower frequency in tumor tissues compared to adjacent tissues, whereas regulatory T cells and tumor-associated macrophages (TAMs) were significantly increased, indicating strong suppressive TIME in GC. Incorporated with oncogenic genomic traits, we found that the unique immunophenotype was interactively shaped by a specific GC gene signature across tumor progression. Earlier-stage GC lesions with IFN signaling enrichment harbored significantly altered T-cell compartments while advanced GC featured by metabolism signaling activation was accumulated by TAMs. Interestingly, PD-1 expression on CD8+ T cells was relatively higher in earlier-stage GC patients, indicating that these patients may derive more benefits from PD-1 inhibitors. The dynamic properties of diverse immune cell types revealed by our study provide new dimensions to the immune landscape of GC and facilitate the development of novel immunotherapy strategies for GC patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article